FDA AI Review Tools: What the Elsa Transition Means for Regulatory Strategy
The FDA is migrating its internal AI tool Elsa from Claude to Gemini. Learn how this shift may affect regulatory reviews, submission strategy, and FDA timelines. For companies preparing medical device or pharmaceutical regulatory submissions to the FDA, these developments reinforce the importance of clear documentation and proactive regulatory planning. What Is Elsa? The FDA’s […]
